Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domatinostat and Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma
NCT04874831Phase 2Withdrawn
- Sponsor
- 4SC AG
- Start
- Nov 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Domatinostat in Merkel cell carcinoma (MCC), sponsored by 4SC AG. Planned start Nov 2021; status: withdrawn.
02
Drugs
Domatinostat
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04874831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874831.